eligibility_summary
Adults 18–75 with untreated HGBCL/DLBCL (incl transformed) and MYC rearrangement (single/double/triple hit), stage II+, IPI 2–5, measurable disease, ECOG 0–2, adequate organ function. Exclude prior DLBCL tx (except brief steroids or 1 cycle R-CHOP/DA-R-EPOCH), severe mAb allergy, PML/CAEBV, HBV/HCV PCR+ or HIV, solid organ transplant, HLH, autoimmune disease (exceptions), CNS involvement, significant heart/lung disease, active infection, abnormal liver/coag labs, no cannabis/herbal, contraception required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib/II single-arm trial in untreated MYC-rearranged HGBCL/DLBCL tests: 1) Mosunetuzumab (Lunsumio, bispecific monoclonal antibody, CD20×CD3 T‑cell engager) IV plus 2) DA‑EPOCH chemotherapy: etoposide (epipodophyllotoxin, topoisomerase II inhibitor), doxorubicin (anthracycline, DNA intercalator/topo II inhibition/ROS), vincristine (vinca alkaloid, microtubule inhibitor), cyclophosphamide (alkylating agent, DNA crosslinking), prednisone (glucocorticoid, lympholytic). Tocilizumab (anti–IL‑6R mAb) may be used for CRS management. Targets/pathways: CD20+ malignant B cells, T‑cell receptor/CD3–mediated T‑cell activation and cytotoxic synapse formation, DNA replication/repair and mitotic spindle (chemo), glucocorticoid receptor signaling. MYC rearrangement defines disease biology, MYC itself is not directly targeted.